Clinical immunology最新文献

英文中文

Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis 先天性免疫错误患者的临床外显子组测序数据：队列水平的诊断率和系统性再分析的益处。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-10-05 DOI: 10.1016/j.clim.2024.110375

While next generation sequencing has expanded the scientific understanding of Inborn Errors of Immunity (IEI), the clinical use and re-use of exome sequencing is still emerging. We revisited clinical exome data from 1300 IEI patients using an updated in silico IEI gene panel. Variants were classified and curated through expert review. The molecular diagnostic yield after standard exome analysis was 11.8 %. Through systematic reanalysis, we identified variants of interest in 5.2 % of undiagnosed patients, with 76.7 % being (candidate) disease-causing, providing a (candidate) diagnosis in 15.2 % of our cohort. We find a 1.7 percentage point increase in conclusive molecular diagnoses. We find a high degree of actionability in patients with a genetic diagnosis (76.4 %). Despite the modest absolute diagnostic gain, these data support the benefit of iterative exome reanalysis in IEI patients, conveying the notion that our current understanding of genes and variants involved in IEI is by far not saturated.

虽然新一代测序技术拓展了人们对先天性免疫错误（IEI）的科学认识，但外显子组测序技术的临床应用和再利用仍处于起步阶段。我们使用最新的硅学 IEI 基因面板重新研究了 1300 例 IEI 患者的临床外显子组数据。通过专家审查对变异进行了分类和策划。标准外显子组分析后的分子诊断率为 11.8%。通过系统性再分析，我们在 5.2% 的未确诊患者中发现了感兴趣的变异，其中 76.7% 是（候选）致病变异，为 15.2% 的患者提供了（候选）诊断。我们发现确诊的分子诊断率提高了 1.7 个百分点。我们发现基因诊断患者的可操作性很高（76.4%）。尽管诊断的绝对收益不大，但这些数据支持了对 IEI 患者进行外显子组迭代再分析的益处，并传达了这样一个理念：我们目前对 IEI 相关基因和变异的了解还远远没有达到饱和。

引用次数: 0

Protective immunity to repeated COVID-19 breakthrough infections 对 COVID-19 反复突破性感染的保护性免疫。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-30 DOI: 10.1016/j.clim.2024.110374

引用次数: 0

Anti-interferon gamma-inducible protein 16 antibodies: Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on a multicenter cohort study 抗干扰素γ诱导蛋白16抗体：基于多中心队列研究的特发性间质性肺炎新型自身抗原鉴定及其临床特征。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-30 DOI: 10.1016/j.clim.2024.110372

Autoantibodies are detected in idiopathic interstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in IIPs. We screened 295 IIP patients using a ³⁵S-methionine labeled protein immunoprecipitation assay. Candidate autoantigens were identified via protein array and confirmed by immunoprecipitation. Six sera from 295 IIP patients immunoprecipitated common tetrameric proteins (100 kDa). The protein array identified interferon gamma-inducible protein 16 (IFI16) as the candidate autoantigen. Patients with anti-IFI16 antibodies received immunosuppressants less frequently. Five-year survival rates were 50 %, 69 %, and 63 % (P = 0.60), and acute exacerbation-free rates were 50 %, 96 %, and 84 % (P = 0.15) for patients with anti-IFI16, anti-aminoacyl tRNA antibodies, and others. Anti-IFI16 is a novel autoantibody in IIPs. Patients with this antibody often receive less immunosuppressive therapy and could have a poor prognosis. Further research is needed to refine patient stratification and management.

特发性间质性肺炎（IIPs）中可检测到自身抗体，但没有明确的结缔组织病诊断，其临床意义尚不清楚。本研究旨在确定特发性间质性肺炎中的一种新型自身抗体。我们使用 35S 蛋氨酸标记蛋白质免疫沉淀法对 295 例 IIP 患者进行了筛查。通过蛋白质阵列确定了候选自身抗原，并通过免疫沉淀进行了确认。来自 295 名 IIP 患者的六份血清免疫沉淀了常见的四聚体蛋白（100 kDa）。蛋白质阵列确定干扰素γ诱导蛋白16（IFI16）为候选自身抗原。抗IFI16抗体患者接受免疫抑制剂的频率较低。抗IFI16抗体、抗氨基酸tRNA抗体和其他抗体患者的五年生存率分别为50%、69%和63%（P = 0.60），无急性加重率分别为50%、96%和84%（P = 0.15）。抗IFI16是IIPs中的一种新型自身抗体。有这种抗体的患者通常接受的免疫抑制治疗较少，预后可能较差。需要进一步研究以完善患者分层和管理。

{"title":"Anti-interferon gamma-inducible protein 16 antibodies: Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on a multicenter cohort study","authors":"","doi":"10.1016/j.clim.2024.110372","DOIUrl":"10.1016/j.clim.2024.110372","url":null,"abstract":"<div><div>Autoantibodies are detected in idiopathic interstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in IIPs. We screened 295 IIP patients using a <sup>35</sup>S-methionine labeled protein immunoprecipitation assay. Candidate autoantigens were identified via protein array and confirmed by immunoprecipitation. Six sera from 295 IIP patients immunoprecipitated common tetrameric proteins (100 kDa). The protein array identified interferon gamma-inducible protein 16 (IFI16) as the candidate autoantigen. Patients with anti-IFI16 antibodies received immunosuppressants less frequently. Five-year survival rates were 50 %, 69 %, and 63 % (<em>P</em> = 0.60), and acute exacerbation-free rates were 50 %, 96 %, and 84 % (<em>P</em> = 0.15) for patients with anti-IFI16, anti-aminoacyl tRNA antibodies, and others. Anti-IFI16 is a novel autoantibody in IIPs. Patients with this antibody often receive less immunosuppressive therapy and could have a poor prognosis. Further research is needed to refine patient stratification and management.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broad applicability of the Goldspire™ platform for the treatment of solid tumors Goldspire™ 平台广泛适用于实体瘤的治疗。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-28 DOI: 10.1016/j.clim.2024.110373

Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (NCT02507583). A Phase 2b study (NCT04485949) recently completed enrollment.

Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.

Goldspire™ 是一种个性化免疫疗法平台，它将整个肿瘤衍生细胞与生物扩散室（BDC；孔径 0.1 μm）中针对胰岛素样生长因子-1 受体（IGF-1R）的反义寡核苷酸（IMV-001）结合在一起。BDCs暴露于5-6Gy，并在腹部部位植入约48小时，以传递抗原载荷和免疫刺激因子来训练免疫系统。主导产品IGV-001在新诊断胶质母细胞瘤（ndGBM）患者中进行了1a和1b期试验评估（NCT02507583）。一项 2b 期研究（NCT04485949）最近完成了入组。在膀胱癌、胰腺癌、卵巢癌、结肠直肠癌或肾癌小鼠中，使用 Goldspire 生产的肿瘤特异性产品进行预防性治疗可限制肿瘤进展并延长总生存期。抗-PD-1可增强这种免疫疗法的疗效；在原位癌和黑色素瘤模型中，联合疗法优于单一疗法。最后，Goldspire 在与匹配的免疫细胞共同培养的过程中，激发了针对患者子宫内膜肿瘤衍生产物的免疫 T 细胞活化和记忆表型。

{"title":"Broad applicability of the Goldspire™ platform for the treatment of solid tumors","authors":"","doi":"10.1016/j.clim.2024.110373","DOIUrl":"10.1016/j.clim.2024.110373","url":null,"abstract":"<div><div>Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (<span><span>NCT02507583</span><svg><path></path></svg></span>). A Phase 2b study (<span><span>NCT04485949</span><svg><path></path></svg></span>) recently completed enrollment.</div><div>Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bisphenol A triggers activation of ocular immune system and aggravates allergic airway inflammation 双酚 A 会引发眼部免疫系统激活，加重过敏性气道炎症。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-28 DOI: 10.1016/j.clim.2024.110370

Bisphenol A (BPA) is widely used in manufacturing plastic products, and it has been reported that exposure through the airway or orally aggravates allergic airway inflammation. Because BPA is detected in the atmosphere and indoor environments, the eyes can also be exposed to BPA. After ocular exposure to BPA and antigen via eye drops, we observed enhanced antigen uptake of antigen-presenting cells (APCs) in tear duct-associated lymphoid tissue (TALT). Additionally, we observed the formation of germinal center (GC) B cells in TALT and induction of allergic airway inflammation in mice sensitized with BPA and antigen via eye drops, followed by airway antigen exposure. We also found that DNAX-activating protein of 12 kDa (DAP12)-deficient mice displayed impaired activation of APCs enhanced by ocular exposure to BPA. These results indicate that ocular sensitization to BPA and allergen triggers allergic inflammation via TALT activation, and that DAP12 might be a key molecule for modulating the ocular immune system.

双酚 A（BPA）被广泛用于制造塑料产品，据报道，通过呼吸道或口服接触双酚 A 会加重过敏性气道炎症。由于大气和室内环境中都能检测到双酚 A，因此眼睛也可能接触到双酚 A。通过滴眼液将双酚 A 和抗原暴露于眼部后，我们观察到泪管相关淋巴组织（TALT）中的抗原呈递细胞（APC）对抗原的吸收增强。此外，我们还观察到泪管相关淋巴组织（TALT）中形成了生殖中心（GC）B 细胞，并通过滴眼液诱导了对双酚 A 和抗原过敏的小鼠的过敏性气道炎症。我们还发现，DNAX-活化蛋白 12 kDa（DAP12）缺陷小鼠在眼部暴露于双酚 A 的情况下，APCs 的活化能力受损。这些结果表明，眼部对双酚 A 和过敏原的致敏会通过 TALT 激活引发过敏性炎症，而 DAP12 可能是调节眼部免疫系统的关键分子。

引用次数: 0

Immune response in vaccinated healthcare workers with frequent COVID-19 infections is characterised by blunted IFNγ and IL-2 responses to SARS-CoV-2 variants 频繁感染 COVID-19 的接种过疫苗的医护人员对 SARS-CoV-2 变体的免疫反应特点是 IFNγ 和 IL-2 反应减弱。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-27 DOI: 10.1016/j.clim.2024.110371

Healthcare workers (HCWs) are at increased risk of SARS-CoV-2 infection. Despite widespread vaccination, some HCWs develop frequent symptomatic infection. We hypothesised that HCWs with frequent symptomatic COVID-19 have impaired T and B cell mediated immunity to SARS-CoV-2.

Vaccinated HCWs with no prior COVID infection (n = 9), asymptomatic recent infection (n = 10), and frequent recent infection (n = 15) were recruited from a longitudinal HCW cohort study. Whole blood stimulation with SARS-CoV-2 variants (Wuhan, B.1.617, BA.2, BA.2.75, BA.4/5, XBB.1.5, BQ.1.1) was performed, with IFNγ and IL-2 responses, total IgG produced, and anti-Spike antibody neutralising capacity measured.

Frequent infections had similar IFNγ and IL-2 responses to the never infected group, with significantly higher responses in the asymptomatic group. The frequent cohort had higher IgG responses to Delta and BA.4/5 and higher neutralising capacity against Omicron variants. An immune signature of blunted IL-2 and IFNγ in frequent infections may identify HCWs at increased risk of further infection.

医护人员（HCWs）感染 SARS-CoV-2 的风险增加。尽管广泛接种了疫苗，但一些医护人员仍经常出现无症状感染。我们假设，频繁出现 COVID-19 症状的医护人员的 T 细胞和 B 细胞介导的 SARS-CoV-2 免疫力受损。我们从一项纵向HCW队列研究中招募了既往未感染COVID（9人）、近期无症状感染（10人）和近期频繁感染（15人）的已接种疫苗的HCW。用 SARS-CoV-2 变体（武汉、B.1.617、BA.2、BA.2.75、BA.4/5、XBB.1.5、BQ.1.1）进行全血刺激，测量 IFNγ 和 IL-2 反应、产生的总 IgG 和抗史派克抗体中和能力。频繁感染组的 IFNγ 和 IL-2 反应与从未感染组相似，而无症状组的反应明显更高。频繁感染组对Delta和BA.4/5的IgG反应较高，对Omicron变体的中和能力也较高。在频繁感染的人群中，IL-2和IFNγ反应减弱的免疫特征可能会识别出进一步感染风险增加的高危工人。

{"title":"Immune response in vaccinated healthcare workers with frequent COVID-19 infections is characterised by blunted IFNγ and IL-2 responses to SARS-CoV-2 variants","authors":"","doi":"10.1016/j.clim.2024.110371","DOIUrl":"10.1016/j.clim.2024.110371","url":null,"abstract":"<div><div>Healthcare workers (HCWs) are at increased risk of SARS-CoV-2 infection. Despite widespread vaccination, some HCWs develop frequent symptomatic infection. We hypothesised that HCWs with frequent symptomatic COVID-19 have impaired T and B cell mediated immunity to SARS-CoV-2.</div><div>Vaccinated HCWs with no prior COVID infection (<em>n</em> = 9), asymptomatic recent infection (<em>n</em> = 10), and frequent recent infection (<em>n</em> = 15) were recruited from a longitudinal HCW cohort study. Whole blood stimulation with SARS-CoV-2 variants (Wuhan, B.1.617, BA.2, BA.2.75, BA.4/5, XBB.1.5, BQ.1.1) was performed, with IFNγ and IL-2 responses, total IgG produced, and anti-Spike antibody neutralising capacity measured.</div><div>Frequent infections had similar IFNγ and IL-2 responses to the never infected group, with significantly higher responses in the asymptomatic group. The frequent cohort had higher IgG responses to Delta and BA.4/5 and higher neutralising capacity against Omicron variants. An immune signature of blunted IL-2 and IFNγ in frequent infections may identify HCWs at increased risk of further infection.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease 抑制 CXCL5 可保护糖尿病肾病患者的肾小管上皮细胞，从而改善肾功能。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-24 DOI: 10.1016/j.clim.2024.110369

Inflammation is one of exacerbating factors of diabetic kidney disease (DKD). Upregulated CXCL5 is found in clinical and experimental diabetes studies. This study aimed to investigate the impact and mechanism of CXCL5 on DKD. DKD patients with different levels of urine albumin-to-creatinine ratio were enrolled. Lepr^db/db mice and CXCL5-knockout diabetic mice were used as mouse models for DKD. Human renal tubular epithelial cells were used for in vitro experiments. Circulating CXCL5 were increased in DKD patients compared to the non-DKD subjects. CXCL5 inhibition through CXCL5-neutralizing antibodies or genetic knockout improved kidney function and ameliorated tubular injury and renal fibrosis. In high-glucose-stimulated tubular epithelial cells, administration of CXCL5-neutralizing antibodies or siRNA resulted in reduced phospho-JNK/c-JUN/p65 and the downstream inflammatory, fibrotic, and apoptotic protein expressions. Administration of CXCR2 and JNK inhibitors impeded the CXCL5-induced tubular epithelial cell damages. In conclusion, these findings indicated that anti-CXCL5 strategies may be potential treatments for DKD.

炎症是糖尿病肾病（DKD）的恶化因素之一。在临床和实验性糖尿病研究中都发现了 CXCL5 的上调。本研究旨在探讨CXCL5对DKD的影响和机制。研究人员招募了不同尿白蛋白与肌酐比值水平的 DKD 患者。以 Leprdb/db 小鼠和 CXCL5 基因剔除糖尿病小鼠为 DKD 小鼠模型。体外实验使用人肾小管上皮细胞。与非 DKD 患者相比，DKD 患者循环中的 CXCL5 增加。通过 CXCL5 中和抗体或基因敲除抑制 CXCL5 可改善肾功能，减轻肾小管损伤和肾脏纤维化。在高葡萄糖刺激的肾小管上皮细胞中，给予 CXCL5 中和抗体或 siRNA 可减少磷酸-JNK/c-JUN/p65 以及下游炎症、纤维化和凋亡蛋白的表达。服用 CXCR2 和 JNK 抑制剂可抑制 CXCL5 诱导的肾小管上皮细胞损伤。总之，这些研究结果表明，抗CXCL5策略可能是治疗DKD的潜在方法。

引用次数: 0

Insights into the multifaceted role of interleukin-37 on human immune cell regulation 洞察白细胞介素-37 对人类免疫细胞调节的多方面作用。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-20 DOI: 10.1016/j.clim.2024.110368

Autoinflammatory diseases, while having a variety of underlying causes, are mediated by dysfunctional innate immune responses. Therefore, standard treatments target innate cytokines or block their receptors. Despite excellent responses in some patients, first-line treatments fail in others, for reasons which remain to be understood.

We studied the effects of IL-37, an anti-inflammatory cytokine, on immune cells using multi-omics profiling of 325 healthy adults. Our findings show that IL-37 is associated with inflammation control and generally reduced immune cell activity. Further, genetic variants in IL37 are associated with impaired trained immunity, a memory phenotype of innate immune cells contributing to autoinflammation. To underpin the medical potential of IL-37, an explorative cohort of seven autoinflammatory disorders was built. In vitro stimulation experiments argue for recombinant IL-37 as a potential therapy in IL-6-, and IL-22-driven conditions.

Concluding, IL-37 is highlighted as a cytokine with broad anti-inflammatory functions, implicating its potential as therapeutic intervention.

自身炎症性疾病的根本原因多种多样，但都是由功能失调的先天性免疫反应介导的。因此，标准治疗以先天性细胞因子或阻断其受体为目标。尽管一线治疗在一些患者中取得了很好的疗效，但在另一些患者中却失败了，其原因尚不清楚。我们通过对 325 名健康成年人进行多组学分析，研究了抗炎细胞因子 IL-37 对免疫细胞的影响。我们的研究结果表明，IL-37 与炎症控制和免疫细胞活性普遍降低有关。此外，IL37 的遗传变异与训练有素的免疫力受损有关，而训练有素的免疫力是先天性免疫细胞的一种记忆表型，会导致自身炎症。为了证实 IL-37 的医疗潜力，我们建立了一个由七种自身炎症疾病组成的探索性队列。体外刺激实验证明，重组 IL-37 有可能治疗 IL-6 和 IL-22 驱动的疾病。总之，IL-37 是一种具有广泛抗炎功能的细胞因子，具有治疗干预的潜力。

{"title":"Insights into the multifaceted role of interleukin-37 on human immune cell regulation","authors":"","doi":"10.1016/j.clim.2024.110368","DOIUrl":"10.1016/j.clim.2024.110368","url":null,"abstract":"<div><div>Autoinflammatory diseases, while having a variety of underlying causes, are mediated by dysfunctional innate immune responses. Therefore, standard treatments target innate cytokines or block their receptors. Despite excellent responses in some patients, first-line treatments fail in others, for reasons which remain to be understood.</div><div>We studied the effects of IL-37, an anti-inflammatory cytokine, on immune cells using multi-omics profiling of 325 healthy adults. Our findings show that IL-37 is associated with inflammation control and generally reduced immune cell activity. Further, genetic variants in <em>IL37</em> are associated with impaired trained immunity, a memory phenotype of innate immune cells contributing to autoinflammation. To underpin the medical potential of IL-37, an explorative cohort of seven autoinflammatory disorders was built. <em>In vitro</em> stimulation experiments argue for recombinant IL-37 as a potential therapy in IL-6-, and IL-22-driven conditions.</div><div>Concluding, IL-37 is highlighted as a cytokine with broad anti-inflammatory functions, implicating its potential as therapeutic intervention.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521661624004777/pdfft?md5=4e2014b2c0acbcfe8b52c99b9a034331&pid=1-s2.0-S1521661624004777-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcriptomic studies unravel the molecular and cellular complexity of systemic lupus erythematosus: A review 转录组研究揭示了系统性红斑狼疮分子和细胞的复杂性：综述

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-16 DOI: 10.1016/j.clim.2024.110367

Transcriptomic analysis plays a vital role in investigating Systemic Lupus Erythematosus (SLE), a complex autoimmune disease characterized by diverse clinical manifestations. This approach has yielded valuable insights into gene expression patterns and molecular regulatory mechanisms involved in SLE pathogenesis. Notably, interferon-stimulated gene (ISG) signatures are significantly upregulated in immune cells, skin, and kidney. Although a correlation with serological parameters and clinical symptoms has been proposed, the association with global disease activities remains controversial. Key findings in the field include an upregulated plasmablast signature, which positively correlates with disease activity; a neutrophil signature associated with lupus nephritis; and a decreased lymphocyte signature, reflecting lymphopenia. Tissue-level studies highlight the critical role of infiltrating immune cells in organ damage. Future research should leverage advanced technologies and integrate multi-omics data to deepen our understanding of SLE's molecular underpinnings, facilitating the development of targeted therapies.

系统性红斑狼疮（SLE）是一种复杂的自身免疫性疾病，临床表现多种多样。这种方法为了解系统性红斑狼疮发病机制中的基因表达模式和分子调控机制提供了宝贵的信息。值得注意的是，干扰素刺激基因（ISG）特征在免疫细胞、皮肤和肾脏中明显上调。虽然有人提出了与血清学参数和临床症状的相关性，但与整体疾病活动的关联仍存在争议。该领域的主要发现包括与疾病活动呈正相关的浆细胞特征上调；与狼疮肾炎相关的中性粒细胞特征；以及反映淋巴细胞减少的淋巴细胞特征下降。组织层面的研究强调了浸润免疫细胞在器官损伤中的关键作用。未来的研究应利用先进技术并整合多组学数据，以加深我们对系统性红斑狼疮分子基础的了解，从而促进靶向疗法的开发。

引用次数: 0

High symptom burden in female X-linked chronic granulomatous disease carriers 女性X连锁慢性肉芽肿病携带者的高症状负担

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology

Pub Date : 2024-09-13 DOI: 10.1016/j.clim.2024.110364

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical immunology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀